Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The approval is based on data from CASSIOPEIA, an open-label, randomized, active-controlled phase 3 study.
Two androgen receptor inhibitors improved survival by 33% in men with metastatic prostate cancer that responds to hormone therapy.
Darzalex in combination with lenalidomide and dexamethasone is for people who are ineligible for an autologous stem cell transplant.
An advanced study compared intravenous infusions and subcutaneous injections of the antibody treatment.
Four-drug regimen improves response in people being treated for the first time.
Erleada delayed cancer progression and death by two years in a Phase III trial.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.